Who makes Testolactone undecanoate?

Testolactone undecanoate is developed by Medical University of Vienna.

What development phase is Testolactone undecanoate in?

Testolactone undecanoate is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Testolactone undecanoate

Medical University of Vienna · FDA-approved active Small molecule Quality 2/100

Testolactone undecanoate, marketed by the Medical University of Vienna, is a drug with a key composition patent expiring in 2028. Its primary strength lies in its current market presence, leveraging the unique mechanism of action for its primary indication. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Testolactone undecanoate
Also known as	Nebido®
Sponsor	Medical University of Vienna
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Sex Steroids and the Serotonin Transporter (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Testolactone undecanoate CI brief — competitive landscape report
Testolactone undecanoate updates RSS · CI watch RSS
Medical University of Vienna portfolio CI